CompletedPhase 2NCT01187238
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chinese Academy of Medical Sciences
- Principal Investigator
- Li Gao, MDCancer Institute and Hospital, Chinese Academy of Medical Sciences
- Intervention
- cisplatin(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2010 – 2017
Study locations (3)
- Cancer hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Zhejiang province cancer hospital, Hangzhou, Zhejiang, China
- Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01187238 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07584499Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsSun Yat-sen University
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGPHASE3NCT07459296Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCFirst Affiliated Hospital of Guangxi Medical University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu